Treats major depressive disorder. ANDA 202036, held by Yaopharma. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 202036 (Venlafaxine Hydrochloride), held by Yaopharma, was first approved by FDA on May 28, 2015, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 28, 2015 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 25MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 50MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 100MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Aug 18, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 21, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 14, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 14, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 14, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 14, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 28, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters